Actinogen is developing a revolutionary oral therapeutic, Xanamem^®, which controls levels of the “stress hormone” cortisol in the brain, with the goal of improving the lives of patients and their families. Topline results from our first pivotal Alzheimer’s trial, evaluating its potential to slow disease progression, are expected in November 2026.

ACW pivotal Alzheimers trial database lock - results mid-Nov

Actinogen has announced formal achievement of the ‘database lock’ milestone in its XanaMIA phase 2b/3 Alzheimer’s disease trial. Guidance for trial topline final results readout has been narrowed to mid-November this year.

ACW September 2026 quarterly activity report & Appendix 4C

Actinogen has released its quarterly activity report and Appendix 4C for the three-month period ended 30 September 2026.

XanaMIA pivotal Alzheimer's disease trial completes final patient visit

Actinogen has announced that the final trial participant visit has been completed in its XanaMIA phase 2b/3 Alzheimer’s disease clinical trial. The topline final results readout for the trial remains on track for November this year.

Xanamem oral presentation at 6th International Conference on Cognitive and Behavioral Neurosciences in Paris

ACW CMO, Dr Dana Hilt, presented the latest insights on Xanamem at the 6th International Conference on Cognitive and Behavioral Neurosciences in Paris, highlighting its potential as a novel treatment for neuropsychiatric and neurodegenerative disorders.

FY 2026 financial results - pivotal Alzheimer’s trial results imminent

FY26 Appendix 4E and annual report

Access our FY26 Appendix 4E and Annual Report, providing a comprehensive overview of financial and operational performance for the year ended 30 June 2026.

ACW presents at Bioshares Summit 2026

Actinogen presented a corporate presentation highlighting Xanamem and its scientific rationale in Alzheimer’s disease. The presentation explores the role of cortisol in the brain and Xanamem’s potential to reduce elevated cortisol through inhibition of the 11β-HSD1 enzyme.